Oku Digital Health Launches to Transform Eye Exams into Early Disease Detection Tools
News related to:Oku Digital Health · 2 min read
LA JOLLA, Calif., Oct. 06, 2026 /CourierPR/ -- Oku Digital Health, an AI-powered digital health company, has launched globally from Topcon Healthcare, aiming to transform routine eye exams into a gateway for early disease detection and accelerated clinical development. The company, which connects eye insights to whole-body health, is built on Topcon's infrastructure and operationalizes oculomics across a network of over 10,000 care locations.
According to the U.S. Centers for Disease Control and Prevention (CDC), 90% of the $5.3 trillion annual U.S. healthcare spend targets chronic and mental health conditions. Several of these conditions are associated with measurable signals in the eye that can be detected before diagnosis. Advancements in AI algorithms and oculomics now enable clinicians to analyze eye data for earlier detection of signs associated with health conditions, including cardiovascular disease, kidney disease, and other systemic illnesses.
Oku puts what the eye reveals in the hands of those who can act on it, clinicians and researchers across eye care, primary care, and drug development.
Built on Topcon's global installed base of over 50,000 diagnostic devices, Oku combines AI-supported diagnostics, electronic health record (EHR) integration, and referral workflows to connect healthcare providers, including primary care, optometry, ophthalmology, and specialists, to support early intervention and disease management. Pharmaceutical partners can also benefit from patient data and real-world evidence for drug development and precision medicine.
Oku's founding leadership team brings expertise from technology disruptors such as Microsoft and NVIDIA, as well as leading-edge research and academic institutions. The team includes: - Ali Tafreshi, CEO, who remains the Chief Strategy Officer for Topcon Corp., Eyecare Business Division, and the CEO of Topcon Healthcare Inc. - Trent Norris, COO, previously the Global Head of Business Development - Digital Health at NVIDIA and Founder of Blue Pelican Health. - Matthew Lungren, MD, MPH, Chief Data AI Officer, an Adjunct Professor - Biomedical Data Science at Stanford University School of Medicine. - Daniela Ferrara, MD, PhD, FASRS, FARVO, Chief Medical Officer, an Assistant Professor of Ophthalmology at Tufts University School of Medicine. - Jacques Gilbert, Chief Strategy and Business Development Officer, who successfully exited three start-ups and previously served as Vice President - Healthcare Strategy, Partnerships, and M&A at Microsoft.
Oku will make its debut at the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans from October 9 to 12, 2026. Attendees can meet the Oku team and explore its solutions within the Topcon Healthcare booth at AAO (1737). Learn more about Oku’s provider solutions here and its pharma solutions here.
The company has screened over 2.2 million patients outside of traditional eye care, leveraging its extensive network and advanced technology to support earlier interventions and disease management. Oku's launch represents a significant step in connecting eye health with broader patient health data, potentially transforming the landscape of early disease detection and clinical development.